BCL-2, BAX, TGF-β and FR-ɑ expression in lung cancer cells after MTX, ABL, and MTX-ABL (1: 4) solid dispersion treatment.

BCL-2, BAX, TGF-β and FR-ɑ expression in lung cancer cells after MTX, ABL, and MTX-ABL (1: 4) solid dispersion treatment.

<p>BCL-2, BAX, TGF-β and FR-ɑ expression in lung cancer cells after MTX, ABL, and MTX-ABL (1: 4) solid dispersion treatment.</p>

Saved in:

Bibliographic Details
Main Author:	Samaa Abdullah (20295517) (author)
Other Authors:	Najla Altwaijry (4902364) (author), Meaad Alnakhli (20571086) (author), Ghezlan ALenezi (20571089) (author), Alaa A. Al-Masud (19370050) (author), Hanan Henidi (15351990) (author), Yahya F. Jamous (20571092) (author)
Published:	2025
Subjects:	Medicine Biotechnology Ecology Cancer Plant Biology Space Science Biological Sciences not elsewhere classified xlink "> methotrexate treat lung cancer tgf -&# 946 gastrointestinal simulated media fr -&# 593 pulmonary enhanced distribution oral tablets available lung cancer cells hydroxypropyl methylcellulose encapsulation sustained release character release analysis results mtx resistance modulation mtx physiochemical modulation high mtx concentrations preferential pulmonary distribution novel methotrexate long optimum hpmc amounts hpmc outer coating abl gel product abl solid dispersion optimum mtx hpmc gel abl encapsulation abl dispersion solid dispersions oral administration enhanced efficacy coating using a549 cells optimized mtx mtx alone coated mtx abl ). tricky move ray diffraction poor selectivity mentioned mechanism immunosuppressant following higher using done based different characterizations delivery system cytotoxicity assay commonly used action due 24 h &# 8217
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Cannot write session to /tmp/vufind_sessions/sess_1fgqt0nndtu984ge7i0s9adcqk